Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
纳武利尤单抗和帕博利珠单抗是两种单克隆抗体，它们能阻断程序性死亡受体 1（PD-1，CD279），从而抑制肿瘤特异性免疫反应。这两种药物最近均被批准用于治疗转移性黑色素瘤，纳武利尤单抗也被批准用于治疗非小细胞肺癌。
